# US 11,999,804 B2 · Treatment agent for lysosomal storage disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,999,804 B2
- Document ID: US11999804B2
- Status: Granted
- Kind: B2
- Application number: 16/729,017
- Filed: 2019-12-27
- Published: 2020-06-25
- Granted: 2024-06-04
- Earliest claimed: 2017-06-30
- Assignees: FUJIFILM Corporation; Kyoto Prefectural Public University Corporation
- Applicants: FUJIFILM Corporation; Kyoto Prefectural Public University Corporation
- Inventors: Kentaro Nakamura; Tsukasa Kitahashi; Rie Hando; Satoshi Gojo; Daisuke Kami
- Web page: https://patentgrep.com/patent/US11999804B2

## CPC

- A61K 9/1658: {Proteins, e.g. albumin, gelatin}
- C07K 7/06: having 5 to 11 amino acids
- A61K 9/0024: {Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L)}
- A61K 35/28: Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A61K 35/33: Fibroblasts
- A61K 38/47: acting on glycosyl compounds (3.2), e.g. cellulases, lactases
- A61K 47/42: Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein (oligopeptides having up to five amino acids {A61K47/183}; polyamino acids A61K47/34)
- A61L 27/14: Macromolecular materials
- A61L 27/22: Polypeptides or derivatives thereof {, e.g. degradation products}
- A61L 27/38: {containing added animal cells (organs or tissue containing native cells A61L27/36)}
- A61L 27/44: having a macromolecular matrix
- A61L 27/54: Biologically active materials, e.g. therapeutic substances {(A61L27/227 takes precedence)}
- A61L 27/56: Porous materials, {e.g. foams or sponges}
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 5/0068: {General culture methods using substrates (for specific animal cell type C12N5/06)}
- A61K 9/16: Agglomerates; Granulates; Microbeadlets {; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction (A61K9/20 takes precedence if the final form is a tablet; microspheres with drug-free outer coating, microcapsules A61K9/50; mixture of different granules, microcapsules, (coated) microparticles A61K9/5084; nanoparticles A61K9/51)}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 14/78: Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
- C12N 11/04: entrapped within the carrier, e.g. gel or hollow fibres
- C12N 2533/40: Polyhydroxyacids, e.g. polymers of glycolic or lactic acid (PGA, PLA, PLGA); Bioresorbable polymers
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

An object of the present invention is to provide an excellent treatment agent for a lysosomal storage disease. According to the present invention, there is provided a treatment agent for a lysosomal storage disease including a cell structure which includes a plurality of biocompatible polymer blocks and a plurality of cells of at least one type and in which at least one of the polymer blocks is disposed in gaps between the plurality of cells.

## Claims

### Claim 1

A method of treating a lysosomal storage disease, comprising transplanting a cell structure to a subject in need of a treatment for a lysosomal storage disease, wherein the cell structure includes a plurality of biocompatible polymer blocks and a plurality of mesenchymal stem cells, further wherein at least one of the polymer blocks is disposed in gaps between the plurality of mesenchymal stem cells,
wherein the cells do not overexpress a gene necessary for a therapy of a lysosomal storage disease by introduction of the gene,
wherein the number of mesenchymal stem cells transplanted by the cell structure is 1.0×105 cells/kg to 2.0×108 cells/kg, and
wherein the number of cells to be administered to the subject is 1.0×105 cells/kg to 2.0×108 cells/kg,
provided that the lysosomal storage disease is not metachromatic leukodystrophy, Hurler syndrome, or Hunter syndrome.

### Claim 2 (depends on 1)

The method according to claim 1,
wherein the cells include at least a mesenchymal stem cell derived from a human or a dog.

### Claim 3 (depends on 1)

The method according to claim 1,
wherein the cell structure includes 0.0000001 μg to 1 μg of the biocompatible polymer block per cell.

### Claim 4 (depends on 1)

The method according to claim 1,
wherein a size of each of the biocompatible polymer blocks is 10 μm to 300 μm.

### Claim 5 (depends on 1)

The method according to claim 1,
wherein a thickness or a diameter of the cell structure is 100 μm to 3 cm.

### Claim 6 (depends on 1)

The method according to claim 1,
wherein the biocompatible polymer block is formed of a recombinant peptide.

### Claim 7 (depends on 6)

The method according to claim 6,
wherein the recombinant peptide is represented by the following formula,
Formula: A-[(Gly-X-Y)n]m-B
in the formula, A represents any amino acid or any amino acid sequence, B represents any amino acid or any amino acid sequence, n pieces of X each independently represent any amino acid, n pieces of Y each independently represent any amino acid, n represents an integer of 3 to 100, m represents an integer of 2 to 10, and n pieces of Gly-X-Y may be the same as or different from each other.

### Claim 8 (depends on 6)

The method according to claim 6,
wherein the recombinant peptide is any one of a peptide which consists of an amino acid sequence described in SEQ ID NO: 1 or a peptide which consists of an amino acid sequence having 80% or more sequence identity with the amino acid sequence described in SEQ ID NO: 1, and has biocompatibility.

### Claim 9 (depends on 1)

The method according to claim 1,
wherein in the biocompatible polymer block, the biocompatible polymers are cross-linked by heat, an ultraviolet ray, or an enzyme.

### Claim 10 (depends on 1)

The method according to claim 1,
wherein the biocompatible polymer block is in a form of a granule obtained by pulverizing a porous body of the biocompatible polymer.

### Claim 11 (depends on 1)

The method according to claim 1,
wherein the lysosomal storage disease is Fabry disease.

### Claim 12 (depends on 1)

The method according to claim 1,
wherein an amount of globotriaosylsphingosine in a living body is reduced by secreting α-galactosidase A in the living body.

### Claim 13 (depends on 1)

The method according to claim 1, wherein the lysosomal storage disease is not Hurler-Scheie syndrome or Maroteaux-Lamy syndrome.

### Claim 14 (depends on 1)

The method according to claim 1, wherein the biocompatible polymer block is a polypeptide.

### Claim 15 (depends on 1)

The method according to claim 1, wherein the cells are not hematopoietic stem cells, leukocytes, granulocytes, monocytes, B cells, and T cells.

### Claim 16 (depends on 1)

The method according to claim 1, wherein the cells consist of at least a mesenchymal stem cell, and/or a fibroblast.

### Claim 17 (depends on 1)

The method according to claim 1, wherein the number of cells transplanted by the cell structure is 1.0×105 cells/kg to 4.0×107 cells/kg.

### Claim 18 (depends on 1)

The method according to claim 1, wherein the cell structure is transplanted by an administration via a portal vein or by subcutaneous administration.

### Claim 19

A method of treating Fabry disease, comprising transplanting a cell structure to a subject in need of a treatment for Fabry disease, wherein the cell structure includes a plurality of biocompatible polymer blocks and a plurality of fibroblast cells, wherein at least one of the polymer blocks is disposed in gaps between the plurality of fibroblast cells,
wherein the cells do not overexpress a gene necessary for a therapy of Fabry disease by introduction of the gene,
wherein the number of mesenchymal stem cells and/or fibroblasts transplanted by the cell structure is 1.0×105 cells/kg to 2.0×108 cells/kg, and
wherein the number of cells to be administered to the subject is 1.0×105 cells/kg to 2.0×108 cells/kg.
